Sarcomatoid Transitional Cell Carcinoma
NCI Definition: A poorly differentiated transitional cell carcinoma characterized by the presence of malignant cells with spindle cell morphologic features. 
Sarcomatoid transitional cell carcinomas most frequently harbor alterations in TP53, CDKN2A, KRAS, KMT2D, and KDM6A .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, TP53 Exon 7 Mutation, and TP53 Codon 245 Missense are the most common alterations in sarcomatoid transitional cell carcinoma .
There is 1 clinical trial for sarcomatoid transitional cell carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains sarcomatoid transitional cell carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Nilotinib and paclitaxel are the most common interventions in sarcomatoid transitional cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.